CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 128 | +7 | 95.71M | $8.15B | +10 | −2 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | — | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | — |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | — | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | — |
| Q2 2024 | 11 | — | 17.42M | $943.61M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 7.51M | — | $406.87M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passief) | 2.74M | — | $148.41M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passief) | 2.74M | — | $148.41M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 2.36M | — | $127.78M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 2.36M | — | $127.78M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 1.68M | — | $90.92M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 1.68M | — | $90.92M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 858.97K | — | $46.54M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 858.97K | — | $46.54M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Norges Bank ✦ (passief) | 799.66K | — | $43.33M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 534.52K | — | $28.96M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 470.97K | — | $25.52M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 374.85K | — | $20.31M | 0.1% | n/c | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 58.60K | — | $3.17M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 33.40K | — | $1.81M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 33.40K | — | $1.81M | 0.0% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 437 houders, 145.17M aandelen, $8.22B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 3.50K aand · $265,370
Officer, Director · 7.50K aand · $575,700
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie